Compare Amgen, Inc. (AMGN) vs NEOS S&P 500 High Income ETF (SPYI) Price & Performance

Amgen, Inc.Trade

NEOS S&P 500 High Income ETFTrade

Price performance (Past 24H)

Key statistics

Amgen, Inc. vs NEOS S&P 500 High Income ETF — how do they compare? Amgen, Inc. trades at $412.21 (market cap $225.71B), while NEOS S&P 500 High Income ETF trades at $54.18. The key difference: Amgen, Inc. pays a 2.42% dividend while NEOS S&P 500 High Income ETF pays none. Which is the better fit depends on your goals.

	AMGN	SPYI
Market Cap	$225.71B	—
Sector	Health	Income / Options Overlay
52-Week High	$417.20	$54.19
52-Week Low	$271.18	$47.98
Enterprise Value	$269.02B	—
Dividend Yield	2.42%	—

View details →View details →

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Amgen, Inc.

No Aura AI signal available yet.

NEOS S&P 500 High Income ETF

SPYI trades at $54.18, up 0.39% today, with a bullish technical signal driven by moving averages. The ETF focuses on generating high income through an options overlay on the S&P 500, offering monthly dividends. Recent news highlights its role in retirement income strategies, though some articles caution about yield sustainability.

The outlook hinges on volatility-driven income generation, with potential for steady returns if market conditions persist. Risks include declining volatility reducing payouts and principal erosion concerns. Investors should weigh the high yield against the strategy's dependency on options premiums.

Aura AI is an analytical signal, not financial advice — do your own research.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

AMGN

BioCryst hits profitability with strong Q2 revenue, sparking takeover interest in rare disease biotech.24/7 Wall Street · 1 day agoBullish View details →

SPYI

SPYI ETF offers high tax-free yield but with high fees and capped upside in Roth IRAs.24/7 Wall Street · 15 hours agoBearish JPMorgan Equity Premium Income ETF lags peers with lowest yield, prompting cautious stance from investors.Seeking Alpha · 1 day agoNeutral View details →

About Amgen, Inc.

Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).

About NEOS S&P 500 High Income ETF

SPYI is an actively managed ETF designed to generate high monthly income through a data-driven call option strategy on the S&P 500 Index. Unlike traditional covered call funds that often forfeit significant upside, SPYI utilizes a 'call spread' approach—selling near-the-money calls while buying out-of-the-money calls—to capture a portion of equity appreciation in rising markets. It prioritizes tax efficiency by utilizing Section 1256 contracts and tax-loss harvesting to provide investors with high-yield monthly distributions.